Masitinib as a chemosensitizer of canine tumor cell lines: A proof of concept study

Veterinary Journal

Volumn 191, Issue 1, 2012, Pages 131-134

  Thamm, D H ^a   Rose, B ^a   Kow, K ^b   Humbert, M ^c   Mansfield, C D ^c   Moussy, A ^c   Hermine, O ^d   Dubreuil, P ^e,f,g  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b University of Florida College of Veterinary Medicine   (United States)

^c AB Science SA   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e INSERM   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Cancer; Chemosensitizer; Chemotherapy; Dogs; Masitinib

Indexed keywords

DOXORUBICIN; GEMCITABINE; MASITINIB; VINBLASTINE;

ANGIOSARCOMA; ANIMAL CELL; ARTICLE; B CELL LYMPHOMA; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG POTENTIATION; EXPLORATORY RESEARCH; GROWTH INHIBITION; HISTIOCYTIC SARCOMA; IC 50; MASTOCYTOMA; MELANOMA CELL; NONHUMAN; OSTEOSARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DEOXYCYTIDINE; DOG DISEASES; DOGS; DOXORUBICIN; DRUG SYNERGISM; INHIBITORY CONCENTRATION 50; PROTEIN KINASE INHIBITORS; SARCOMA; THIAZOLES; VINBLASTINE;

CANIS FAMILIARIS;

EID: 80052508310     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2011.01.001     Document Type: Article

References (8)

1. Conti P., Castellani M.L., Kempuraj D., Salini V., Vecchiet J., Tete S., Mastrangelo F., Perrella A., De Lutiis M.A., Tagen M., Theoharides T.C. Role of mast cells in tumor growth. Annals of Clinical and Laboratory Science 2007, 37:315-322.
2. Dubreuil P., Letard S., Ciufolini M., Gros L., Humbert M., Castéran N., Borge L., Hajem B., Lermet A., Sippl W., Voisset E., Arock M., Auclair C., Leventhal P.S., Mansfield C.D., Moussy A., Hermine O. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE 2009, 4:e7258. 10.1371/journal.pone.0007258.
3. Elia U., Flescher E. PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate towards sarcoma cells. Neoplasia 2008, 10:1303-1313.
4. Hahn K.A., Oglivie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., Powers B., Leventhal P.S., Kinet J.P., Palmerini F., Dubreuil P., Moussy A., Hermine O. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008, 22:1301-1309.
5. Hahn K.A., Legendre A., Shaw N.G., Phillips B., Oglivie G.K., Prescott D.M., Atwater S.W., Carreras K., Lana S.E., Ladue T., Rusk A., Kinet J.P., Dubreuil P., Moussy A., Hermine O. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. American Journal of Veterinary Research 2010, 71:1354-1361.
6. Humbert M., Castéran N., Letard S., Hanssens K., Iovanna J., Finetti P., Bertucci F., Bader T., Mansfield C.D., Moussy A., Hermine O., Dubreuil P. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS ONE 2010, 5:e9430. 10.1371/journal.pone.0009430.
7. Liao A.T., Chien M.B., Shenoy N., Mendel D.B., McMahon G., Cherrington J.M., London C.A. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002, 100:585-593.
8. Mitry E., Hammel P., Deplanque G., Mornex F., Levy P., Seitz J.F., Moussy A., Kinet J.P., Hermine O., Rougier P., Raymond E. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology 2010, 66:395-403.